Objective To evaluate the natural course of disease progression in patients with Sanfilippo syndrome type B (mucopolysaccharidosis type IIIB), identify potential end points for future therapy trials, and characterize biomarkers related to the disease.
S
anfilippo syndrome type B, or mucopolysaccharidosis (MPS) type IIIB (MPS IIIB), is 1 of 7 MPS types; 1 there are 4 genetically distinct MPS type III subtypes (ie, A, B, C, and D). MPS IIIB, affecting approximately 1 in 250 000 live births, [2] [3] [4] [5] [6] is caused by a mutation in both copies of the alpha-N-acetylglucosaminidase gene (NAGLU), located on chromosome 17q21.1. The most dramatic clinical manifestations of MPS IIIB are neurologic. More than 120 NAGLU mutations have been described, mostly missense mutations, but nonsense mutations, deletions, insertions, and splice-site mutations also exist. 7, 8 This wide allelic heterogeneity presents challenges in identifying genotype-phenotype correlations. 6, 9 Patients with an attenuated phenotype carry at least 1 mild missense mutation, allowing for residual NAGLU activity. 10 Typically manifesting at 1-4 years of age, 6 the most prominent progressive symptoms of MPS IIIB are neurologic. Children appear normal at birth and throughout infancy, and progressive brain injury may initially be misdiagnosed as autism. Only as a child reaches preschool or school age do the symptoms of this debilitating disease become apparent. Lacking treatment, affected children slowly progress through 4 phases from developmental delays, surviving into the second or third decade of life. In its severest form, MPS IIIB culminates in dementia and death by the late teens. 6, 11 A group of patients in The Netherlands with attenuated MPS IIIB had a slow progression of signs that occasionally included nonspecific psychiatric manifestations and were diagnosed in adulthood. 12 A study of patients with MPS IIIA and IIIB in France, Greece, and the United Kingdom found a comparable disease in affected individuals, with similar patterns of delayed language acquisition and cognitive decline, as well as disruptive behavior, especially in those diagnosed before 5 years of age. 6 Diagnosis is suspected by the detection of elevated levels of glycosaminoglycan (GAG) in urine. [13] [14] [15] Definitive laboratory confirmation of a suspected clinical phenotype depends on a comprehensive assessment of urine GAG substrate, deficient NAGLU enzyme activity, and the identification of pathologic mutations. 10, 16 There is no proven effective therapy for MPS IIIB, but encouraging phase 1 results have been reported with enzyme replacement therapy 17 and gene therapy. 18 Management currently is symptomatic. 7 Toxic secondary metabolite accumulation, limited neuronal survival, and neuroinflammatory sequelae, resulting in the loss of cortical gray matter and cognitive skills, are thought to contribute to MPS IIIB pathophysiology.
This study was undertaken to better understand the clinical spectrum and progression rate of MPS IIIB and, therefore, to enable the identification of patient subpopulations characterized by disease stage and phenotype who may benefit from future interventional clinical studies. As with MPS IIIA, 19 a paramount functional manifestation of MPS IIIB is cognitive decline. This study hypothesized that well-standardized measures of development quotient (DQ) and cortical gray matter volume (GMV) could serve as appropriate clinical end points. Clinical, neuroimaging, and biochemical tests were explored to identify potential surrogate end points for future trials.
Methods
This MPS IIIB natural history study, initiated in April 2012, was a multicenter, longitudinal, prospective study (ClinicalTrials.gov: NCT01509768). The study was conducted in compliance with the US Food and Drug Administration, Institutional Review Board regulations in 21 Code of Federal Regulations 56, and the International Conference on Harmonisation Good Clinical Practice guidelines. Written consent and/or assent were provided by the patient or the patient's parent or legal guardian before any study-related procedures were initiated. The study was conducted according to ethical principles of the Declaration of Helsinki, consistent with International Conference on Harmonisation Good Clinical Practice guidelines and applicable regulatory requirements, including 21 CFR Parts 50, 54, 56, and 312.
Medically stable patients who were ≥1 year of age with 2 NAGLU mutations at screening or an enzyme deficiency of ≤10% of the lower limit of the testing laboratory's normal range were enrolled. An upper age limit of 10 years was implemented in March 2013 as an amendment to the study protocol to focus on the younger, childhood age group. The inclusion criteria also required patients to have an age equivalence of ≥1 year as assessed by the Vineland Adaptive Behavior Scales, Second Edition (VABS-II), 20 a parent-reported observational measure. The key exclusion criteria were significant non-MPS IIIB-related central nervous system impairment or behavioral disruption, visual or hearing impairment to a level that could impede neurodevelopmental testing, bleeding disorders, the inability to undergo anesthesia or control seizures, or a history of hematopoietic stem cell or bone marrow transplantation.
Patients were screened within 30 days before study initiation and details of the genotypic mutation, sex, race, age at enrollment (chronological age), age at diagnosis, and head circumference were recorded. Sibling information was not collected in the study. The study had a planned sample size of 25 patients, assuming a 20% dropout rate to assess longitudinal data adequately. Clinical, developmental, imaging, and biochemical assessments were performed over a 4-day period at study initiation (baseline) and then again at 6 months (±14 days) and 12 months (±14 days) poststudy initiation.
Study End Points
Planned standardized tools for the assessment of the neurodevelopmental status and adaptive status of patients were the Bayley Scales of Infant Development, Third Edition (BSID-III), the Kaufman Assessment Battery for Children, Second Edition (KABC-II), and VABS-II. [20] [21] [22] The BSID-III measure evaluates the cognitive, motor, and language cognitive development of infants and toddlers aged 0-42 months. In severely impaired children, DQ (the ratio of age-equivalent score to chronological age) is the accepted metric to avoid the "floor" effect of standardized scores. 19, 23 The KABC-II Nonverbal Ability Scale is a cognitive assessment for patients with normative data aged 3-18 years; as patients were either too young or their level of developmental impairment was too severe, no patients were evaluated using the KABC-II measure. The parent-observational report, VABS-II, consists of 5 key domains of communication, daily living skills, socialization, motor skills, and the adaptive behavior composite. 20 The average VABS-II age-equivalent composite score, calculated without the motor component, has been shown to be strongly associated with the cognitive measures. 23 For that reason, the motor skills component was excluded in the calculation of the composite score in this study.
Health-related quality of life was measured using the Child Health Questionnaire Parent Form, 50 items (CHQ-PF50) and the Infant Toddler Quality of Life (ITQOL), either of which was administered according to the patient's developmental age (age-equivalent score). The CHQ-PF50, encompassing 13 health concepts, was designed for patients aged 5-18 years to measure the physical and psychosocial well-being of children and parents or caregivers of affected children. 24 The ITQOL measures similar concepts for children who are 2 months to 5 years of age. 25 However, ITQOL and CHQ-PF50 data at baseline, 6 months, and 12 months were missing for a large number of patients and are, therefore, not described.
Imaging analyses included serial brain magnetic resonance imaging (MRI) studies followed by automated volumetric analysis. 19, 26 MRI quantitative analyses for all patients in the study were performed at the University of Minnesota (the central reader for MRI data). Automated volumetric Volume 197 • June 2018 analysis of MRI scan data, using the FreeSurfer image analysis suite, generated GMV and CSF volume in ventricles. The extent of hepatosplenomegaly was assessed with abdominal MRI. 27, 28 MRI outcomes were compared with baseline over time. It was hypothesized that the CSF acts as a clinically accessible surrogate tissue wherein biomarkers of MPS IIIB neuropathogenesis can be detected. CSF was obtained via lumbar puncture and tested for heparan sulfate levels using sequential liquid chromatography followed by tandem mass spectroscopy. 29 Urine samples were assessed for GAGs using 1,9-dimethylmethylene blue complexed GAG with spectroscopy. 15, 19, 30 Safety follow-up visits were conducted by telephone at 3 months (±14 days) and 9 months (±14 days) during the study period, and at 7 (±2) days after the 12-month observation period.
Subgroup and Statistical Analyses
As in prior MPS III publications, 6, 19 subgroup analyses of study end points by patients' age at diagnosis (<6 years or ≥6 years) were performed. Genotype-phenotype correlations were not used for classification, as they were too heterogeneous in the MPS IIIB population. The subgroup data were summarized using descriptive statistics. Spaghetti plots were used to visualize trends for individual patients. DQ scores for VABS-II and BSID-III were calculated as a ratio of the mean age-equivalent score and age-equivalent score, respectively, divided by the chronological age of the patient at the time of testing multiplied by 100.
19,23

Results
Nineteen patients aged 1.6-31.7 years were enrolled in the study ( Table I) , 15 of whom were diagnosed at <6 years of age. Fourteen of the enrolled patients completed the study. Two patients withdrew from the study before the 6-month time point in the study and 3 patients withdrew before the end of the 12-month study. Consent for 2 of those patients was withdrawn by caregivers, and 3 patients discontinued for other reasons.
Three patients (15.8%) had a nonsense/missense genotype, 2 patients (10.5%) had a nonsense/nonsense genotype, 3 patients (15.8%) had missense/deletion mutations, and 1 patient (5.3%) had a deletion/deletion genotype ( Table I ; specific genotype details in Table II [available at www.jpeds.com]). The genotype of 1 female patient was not analyzed. All (but one) patients were white, and 57.9% were male. The median age of patients at baseline was 8.4 years (IQR, 6.5-17.1 years) and their median age at diagnosis was 4 years (IQR, 2-5 years). All patients had similar head circumferences, with a median of 56.0 cm (IQR, 54.3-57.8 cm) ( Table I) .
Neurodevelopmental Status
Using an algorithm that included calendar age and ageequivalent scores on the VABS-II, all patients were assigned to the BSID-III measure.
At baseline, the mean BSID-III cognitive age-equivalent score was 17.2 (SD, 7.6) months. Increasing age at enrollment was generally associated with a decrease in BSID-III DQ score (Table I , arranged in order of increasing chronological age). Over the 12-month study period, longitudinal BSID-III cognitive age-equivalent scores were variable (Figure 1, B) . The 2 individuals who were enrolled under the age of approximately 42 months showed consistent increases over 12 months, and those between approximately 62 and 143 months showed no change, or overall downward slopes. Patients older thañ 270 months showed no consistent trends. One patient who was diagnosed before the age of 6 years and who was approximately 42 months of age at enrollment achieved a cognitive age-equivalent score of 40 months at 12 months compared with 28 months at 6 months, but this level of increased cognitive age-equivalent score over 6 months is anomalous. When these data were expressed as DQ scores, a uniform decline was evident in all patients up to the age of approximately 145 months, with 1 exception, reflecting the anomalous gain in cognitive age equivalence within the 6-to 12-month interval, as shown in Figure 1 , B. Older patients who were at the floor of the test had more stable BSID-III DQ scores over the study period. Figure 1 , F shows the mean BSID-III cognitive DQ score for patients diagnosed before or after 6 years of age. Patients diagnosed after 6 years of age had a lower BSID-III cognitive DQ score than those diagnosed before 6 years of age; most patients diagnosed after the age of 6 years were older than those diagnosed before the age of 6 years. For children diagnosed at <6 years of age, the mean cognitive DQ score decreased by 10.3% over the study period.
At baseline, the average of the mean age-equivalent scores for VABS-II was 19.3 (SD, 6.9) months (Table I) . On an individual basis, most patients showed a consistent decline in VABS-II age-equivalent score and DQ score over the 12-month study period (Figure 1, A and C) . Mean VABS-II and BSID-III DQ scores were very similar (Figure 1 , E and F).
Volumetric Analysis of the Brain and Abdomen
Individually, most patients diagnosed at <6 years of age showed a consistent decrease in cortical GMV (Figure 2 , A) and a consistent increase in CSF volume in ventricles over 12 months (Figure 2, B) . Cortical GMV and CSF volume in ventricles for patients diagnosed at ≥6 years of age did not vary greatly over the 12-month study period.
At baseline, the mean spleen volume was 309.9 (SD, 150.5) mL, and the mean liver volume was 1872.2 (SD, 799.7) mL ( Table I) . There was no change in the liver or spleen volumes of patients over the 12-month study period (Figure 3 ; available at www.jpeds.com). Age at diagnosis had no effect on spleen volume, but the patients diagnosed at ≥6 years of age had 1.8 times the liver volume at baseline, 6 months, and 12 months compared with patients diagnosed at <6 years of age (Figure 3) .
Urine GAG and CSF Heparan Sulfate Levels
In healthy children of similar ages to the most common ages in the <6 years and ≥6 years diagnosis age groups, recorded upper limits of urine GAG levels are 10.3 and 5.5 mg/mmol creatinine, respectively. 31 Similarly, upper limits of normal CSF In this study, patients with MPS IIIB had higher mean urine GAG and CSF heparan sulfate levels than would be observed in healthy children (Figure 4) . 19, 31 The mean (SD) CSF heparan sulfate and urine GAG levels at baseline were 5.2 (2.4) and 38.1 (22.3) mg/mmol creatinine, respectively. There was an agedependent decrease in the GAG mg/mmol creatinine ratio in individual patients at baseline, as expected, owing to the normal increase in urine creatinine related to increasing body mass with age 14 (Table I) . Most patients who were younger than approximately 150 months of age had a decline in their urine GAG and CSF heparan sulfate levels over the study period (Figure 4, A and  B) . Patients older than approximately 270 months, however, had more variable GAG and CSF heparan sulfate profiles over the study period.
Safety Findings
Nine patients had 12 adverse events that were classified as related or possibly related to the study procedure or disease (Table III ; available at www.jpeds.com). All except 1 moderately severe adverse event (including those unrelated to the study procedure) were mild. There was only 1 serious adverse event related to the study procedure of bradycardia in a male patient under anesthesia that resolved following interruption of the procedure.
Discussion
Retrospective and natural history studies have sought to characterize the rarely encountered MPS IIIB, 6 ,32,33 but they have not portrayed the change in cognition and MRI data documented in this study. A gap exists in the level of clinical and Figure 1 . Trajectory with study months (for individual patients) and age (across all patients) for A, VABS-II mean ageequivalent score, B, BSID-III cognitive age-equivalent score, C, VABS-II DQ scores, D, BSID-III cognitive DQ scores. Change over the 12-month study period in E, mean VABS-II DQ scores and F, mean BSID-III DQ scores for patients grouped as diagnosed before or after 6 years of age. The VABS-II DQ score was calculated from the mean age-equivalent score by averaging out the age-equivalent score for all of the subdomains excluding domains of gross and fine motor skills. n, number of patients.
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biomarker detail needed to efficiently evaluate novel therapies to treat patients with MPS IIIB. This study provides evidence that cognitive and quantitative MRI data are sensitive markers of change for the disease course. Some missense mutations have been known to cause complete loss of function in some patients, 34 but the attenuated form of the disease in others. 12 The sample size of this study, in addition to the limited current literature on the genotype/ phenotype correlations of NAGLU, means that the study findings cannot be used to compare or predict the functional outcomes of different genotype/phenotype correlations (beyond the scope of this study). In a natural history study of patients with MPS IIIB, Héron et al showed that patients diagnosed before 5 years of age had a faster disease progression, including an earlier loss of social interaction and premature death, than those diagnosed after the age of 5 years. 6 The researchers were unable to identify differences in disease progression by age at diagnosis as, of 5 patients who were over 20 years of age, 2 were diagnosed before the age of 6 years and 3 were diagnosed after the age of 6 years. In addition, all patients in the study had cognitive age equivalents below 2 years of age. At the time of the study, 2 patients in the early diagnosis group survived into their 20s, and the 4 patients in the late diagnosis age group were 12, 24, 28, and 32 years of age. 6 In this study, the 2 youngest patients, aged 20 months and 42 months, had cognitive BSID-III DQs above 50. These patients also had a developmental trajectory indicating continued cognitive growth as measured by age-equivalent score over the 1-year study period. The patient aged 42 months experienced an anomalous increase in both cognitive age-equivalent scores and DQ within the last 6 months of the study. Of the remaining patients aged between 5 and 12 years at baseline, all but 1 patient had significant declines in cognitive DQ and either stable or declining age-equivalent scores. The patient aged 11.9 years, diagnosed after 6 years of age, had increasing cognitive age equivalent and DQ scores over the first 6 months of the study indicating that he may be a slow progressing patient with the attenuated phenotype.
For the grouped patient data, stratified by age at diagnosis, there was a notable congruence between mean BSID-III DQ (a patient-reported measure) and mean VABS-II DQ scores (a parent-or caregiver-reported measure), and these findings were also similar to those previously found for MPS IIIA. 19 Patients who were younger than 6 years old at diagnosis had higher mean VABS-II DQ and mean BSID-III DQ scores than those diagnosed after the age of 6 years, and this was likely due to their generally younger age at evaluation and that they had not declined to the floor of these tests. This determination was based on the primary analysis of the main population, involving all enrolled patients. Further analyses using only patients who had taken the VABS-II or BSID-III assessments at all time points (n = 11) showed very similar results for change from baseline.
In a similar natural history study of 10 patients with MPS IIIB aged 8.6 ± 3 years and 15 patients with MPS IIIA aged 5.0 ± 1.9 years, Truxal et al assessed the cognitive function of patients at baseline, 6 months, and 12 months by Mullen Scales. Cognitive function peaked at the 2.5-to 3-year-old developmental stage but declined significantly with age over 6 months in most subdomains. 35 By 6-8 years of age, Leiter nonverbal IQ standard scores declined toward the test floor, but demonstrated significant mean declines over 6 months in patients aged <7 years and in those with nonverbal IQ score ≥45. There was also a decline in VABS-II composite score with chronological age with a significant decline over 6 months. 35 A comparison with MPS IIIA data 19 suggests that patients with MPS IIIB aged between 5 to almost 13 years showed a similar cognitive decline and level of function. This MPS IIIB study had more patients in the oldest group (≥12 years of age) and fewer patients younger than 5 years of age. Unlike the patients with MPS IIIA, genotyping was unable to predict developmental trajectories as most patients in this study had the missense/missense genotype in NAGLU.
Because most patients in this study were already severely impacted at baseline, a notable change in cognitive function over the 12-month study period was not as robust as it was in the previously reported MPS IIIA study. 19 These results also indicate that to recruit patients into an interventional trial who are sufficiently cognitively intact to ensure that a good outcome is possible, newborn screening to enable early diagnosis would be needed. 19 In the 24-month study of patients with MPS IIIA (ClinicalTrials.gov: NCT01047306), total cortical GMV declined with age in most patients and a correlation with a decline in cognitive status was observed. 19 In this study, a decline in cortical gray matter over time and a corresponding compensatory increase in CSF volume in ventricles were seen in patients with MPS IIIB who entered the study at younger than 12 years of age. This was mirrored by a decline in cognitive BSID-III DQ scores over time for individual patients. Overall, patients older than approximately 270 months had lower but relatively stable BSID-III DQ scores over 12 months of observation. The lower BSID-III DQ scores in these patients may reflect disease duration, although there may be some confounding because of the enrichment of attenuated disease phenotypes in those who survive or are still eligible to participate in such a study beyond their teenage years. Similar to that seen in patients with MPS IIIA who had comparable demographics, the sharp decline in cortical GMV represents gross pathologic changes associated with MPS IIIB and suggests that cognitive decline arises because of the damage or loss of cortical neurons. 19 In this study, 7 of 14 (50.0%) patients had rapidly progressing disease in terms of the steep decline in BSID-III DQ score and cortical GMV in 12 months, whereas in the MPS IIIA study, 19 of 24 (79.2%) patients had sharp . Trajectory with study months (for individual patients) and age (across all patients) for A, urine GAG and B, CSF heparan sulfate. Change over the 12-month study period in C, mean urine GAG and D, mean CSF heparan sulfate for patients grouped as diagnosed before or after 6 years of age. *In the <6 years and ≥6 years diagnosis age groups, the normal GAG levels shown are 10.3 mg/mmol and 5.5 mg/mmol creatinine, respectively (ie, the upper limits of the urine GAG level for the most common equivalent ages in a healthy population as reported by Cambridge Biomedical, Inc.). 31 In the <6 years and ≥6 years diagnosis age groups, the normal CSF heparan sulfate levels shown are 0.443 µmol/L and 0.426 µmol/L, respectively (ie, the upper limits of the CSF heparan sulfate level for the most common equivalent ages in a healthy population as reported in Shapiro et al). 19 Note that our study did not include an analysis in a healthy population.
THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 197 declines in these measurements. 19 Truxal et al also demonstrated ventriculomegaly and a loss of cortical volume in MPS IIIA and MPS IIIB patients by brain MRI. 35 Cortical GMV was already lower than normal at baseline; in a previous study of healthy volunteers aged approximately 14-25 years, total GMV was approximately 700-800 mL, 36 but patients in our study (some of whom were similarly aged) had a GMV ranging from 226 to 577 mL at baseline. The CSF volume in ventricles in healthy subjects is reported to be about 25 mL, 37 reaching its maximum by 5 years of age. 38 Most patients in our study were over the age of 5 years and had a CSF volume in ventricles of 25-153 mL.
Limitations of our study include the short length of followup and the sample size, which is particularly pertinent for patients who were younger than 7 years old at enrollment, those diagnosed at ≥6 years of age, and the extent of missing data for some end points. There was also a wide range in the age of enrollment (1.6-25.7 years for the younger diagnosis age group and 11.9-31.7 years for the older diagnosis age group), resulting in heterogeneity in the stage of disease progression. At study entry, 6 of 19 (31.6%) patients were younger than 7 years old, but only 2 were younger than 5 years old. The limited presence of younger patients in this study does not allow for an understanding of the effects of the disease on development in the early stages, which is when a decline is typically observed. The lack of patients diagnosed at ≥6 years of age also was found in patients with MPS IIIA 19 and may be due to a lower incidence of slower progressing disease. In addition, the DQ data indicate that most of the patients were already at an advanced disease stage at enrollment. Importantly, only the youngest patient (aged 1.6 years) was in the normal range of development at baseline. Despite study limitations, the downward course of the disease in early childhood shown by both cognitive testing and MRI quantitation of cortical gray matter atrophy appears similar to that of MPS IIIA, and both measures can be used to evaluate disease severity and change over time.
Limitations for biomarker assessments were that all patients received concomitant medications during the study, some of which act on the nervous system, alimentary tract, and metabolism, with unknown effects on GAG levels. Improvements in the procedures used to measure CSF heparan sulfate, including advances in liquid chromatography-mass spectrometry and tandem mass spectrometry to increase its sensitivity, will increase its potential usefulness as a pharmacodynamics measure. 29 Despite these limitations, the urine GAG and CSF heparan sulfate levels were highly elevated relative to normal but were stable over a 12-month period (similarly found in a MPS IIIA natural history study 19 ). In a natural history study of MPS IIIA and MPS IIIB patients, Truxal et al found that urine GAG levels were elevated compared with normal but decreased with patient age, approaching normal values in older patients, and one-third of patients had elevated CSF protein levels at baseline. 35 Further evidence is necessary to determine the sensitivity of these biomarkers to disease progression.
Abdominal MRI results, however, were less clear. Although the older diagnosis age group had a greater liver volume than the younger diagnosis age group, these patients also were older upon enrollment (mean age of 23.9 vs 9.0 years). Nevertheless, the liver and spleen volumes in both diagnosis age groups were approximately double the normal range of healthy patients. 27, 28 Comparably, abdominal MRI measurements by Truxal et al revealed that patients with MPS IIIA and patients with MPS IIIB had mean liver and spleen volumes that were 2.2 times and 1.9 times the normal range, respectively, with no significant change over the 1-year study period. 35 There were no notable safety findings or adverse events related to study procedures in this natural history study.
In conclusion, the study results suggest that neurocognitive and adaptive function, and quantitative MRI are appropriate methods to evaluate patients in future efficacy trials for MPS IIIB treatments. Although biomarkers may have prognostic value, further investigations into the use of these biomarkers to track disease severity are warranted. Increased awareness of this rare disease among practitioners is needed. However, newborn screening for an early diagnosis will be necessary to identify patients earlier in the disease stage, at a time when they are more likely to be responsive to therapy. In addition to an earlier diagnosis, there is a need for development of an effective treatment for MPS IIIB to slow the progression of this lethal disease. ■
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